NASDAQ: IKT
Inhibikase Therapeutics Inc Stock Ownership - Who owns Inhibikase Therapeutics?

Insider buying vs selling

Have Inhibikase Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Roberto BelliniDirector2024-10-211,460,000$1.37
$2.00MBuy
Arvind KushDirector2024-10-21145,000$1.37
$198.65kBuy
Amit MunshiDirector2024-10-21365,000$1.37
$500.05kBuy

1 of 1

IKT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when IKT insiders and whales buy or sell their stock.

IKT Shareholders

What type of owners hold Inhibikase Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Sands Capital Life Sciences Pulse Fund II LP14.73%10,950,000$24.09MInsider
Sands Capital Ventures LLC14.73%10,950,000$24.09MInstitution
Soleus Capital Management LP8.51%6,325,000$13.92MInstitution
Fairmount Funds Management LLC8.24%6,125,000$13.48MInstitution
Commodore Capital LP7.97%5,925,000$13.04MInstitution
Perceptive Advisors LLC7.97%5,925,000$13.04MInstitution
Milton H. Werner7.21%5,359,022$11.79MInsider
Adar1 Capital Management LLC6.86%5,103,005$11.23MInstitution
Vanguard Group Inc3.82%2,838,645$6.25MInstitution
Nantahala Capital Management LLC2.95%2,190,000$4.82MInstitution

1 of 3

IKT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
IKT67.36%24.73%Net Buying
INBX73.02%26.98%Net Buying
ACIU27.26%0.00%
FENC4.45%95.55%Net SellingNet Selling
HURA4.95%43.24%

Inhibikase Therapeutics Stock Ownership FAQ

Who owns Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ: IKT) is owned by 67.36% institutional shareholders, 24.73% Inhibikase Therapeutics insiders, and 7.92% retail investors. Sands Capital Life Sciences Pulse Fund II LP is the largest individual Inhibikase Therapeutics shareholder, owning 10.95M shares representing 14.73% of the company. Sands Capital Life Sciences Pulse Fund II LP's Inhibikase Therapeutics shares are currently valued at $24.64M.

If you're new to stock investing, here's how to buy Inhibikase Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.